Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) pipeline Target constitutes close to 30 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 8, 7, 2, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders, Genito Urinary System And Sex Hormones, Infectious Disease, Central Nervous System and Immunology which include indications Thrombosis, Venous Thromboembolism, Bleeding And Clotting Disorders, Arterial Thrombosis, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Thromboembolic Disease, Atrial Fibrillation, Deep Vein Thrombosis (DVT), Hemophilia C (Factor XI Deficiency), Venous (Vein) Thrombosis, Acute Ischemic Stroke, Blood Coagulation, Coronavirus Disease 2019 (COVID-19), Inflammation, Ischemic Stroke, Myocardial Infarction, Neurology, Pulmonary Embolism, Sepsis, Stroke and Thromboembolism.

The latest report Coagulation Factor XI - Drugs In Development, 2022, outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
• The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects
• The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope